USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ACCELERATED MEDICAL DIAGNOSTICS, LLC
Address:
2121 2ND ST, B-101
DAVIS, CA 95616-5472
Phone:
N/A
URL:
N/A
EIN:
461389984
DUNS:
826929015
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $395,519.00 2
SBIR Phase II $1,499,894.00 1

Award List:

Phase 0 carboplatin microdosing diagnostics trial

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$195,550.00
Agency:
HHS
Principal Investigator:
Paul Henderson – (925) 570-1615
Abstract:
We developed a technology called PlatinDx that, based upon preclinical data, can potentially identify chemoresistance in cancer patients before they receive carboplatin or cisplatin therapy. PlatinDx utilizes tracing of subtherapeutic "microdoses" of 14C-labeled carboplatin with… More

OTHER FUNCTIONS PHASE 0 CARBOPLATIN MICRODOSING DIAGNOSTIC TRIAL.

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,499,894.00
Agency:
HHS
Principal Investigator:
Paul Henderson – 925-570-1615
Abstract:
We developed a technology called PlatinDx that, based upon preclinical data, can potentially identify chemoresistance in lung and bladder cancer patients before they receive carboplatin therapy. PlatinDx utilizes tracing of subtherapeutic microdoses of14C-labeled carboplatin with accelerator… More

OTHER FUNCTIONS - RandD BIOMEDICAL (BASIC RESEARCH)

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$199,969.00
Agency:
HHS
Principal Investigator:
Paul Henderson – 925-570-1615
Abstract:
A. Background Information We developed a technology called PlatinDx that, based upon preclinical data, can potentially identify chemoresistance in breast cancer patients before they receive oxaliplatin therapy. PlatinDx utilizes tracing of subtherapeuticmicrodoses of 14C-labeled oxaliplatin with… More